Literature DB >> 6183313

Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.

K Danø, E Dabelsteen, L S Nielsen, K Kaltoft, E L Wilson, J Zeuthen.   

Abstract

A monoclonal antibody against a 52,000 dalton human plasminogen activating enzyme (HPA52) was used for immunofluorescence staining of cultured glioblastoma cells. The fluorescence was located in the cytoplasm of the cells. A pronounced variation in the staining intensity was observed between the individual cells. The specificity of the fluorescent stain was supported by the findings that 1) no staining was obtained with a monoclonal antibody of the same subclass, but with irrelevant specificity (anti-2,4,6-trinitrophenyl); 2) adsorption with HPA52 purified to homogeneity removed the ability of anti-HPA52 to mediate staining; 3) the glioblastoma cells contained HPA52, as measured by enzymatic assay, while melanoma cells that were not stained did not contain HPA52 activity; 4) dexamethasone reduced both the enzymatically determined HPA52 content and the immunofluorescence in parallel, while progesterone affected none of these parameters; 5) we have previously found that culture fluid conditioned by the glioblastoma cells apart from HPA52 does not contain detectable amounts of any protein that binds to anti-HPA52. Several advantages of immunohistochemical detection of plasminogen activators compared with enzyme histochemical methods are discussed, among these that the immunohistochemical method distinguishes between plasminogen activators of different types.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183313     DOI: 10.1177/30.11.6183313

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  13 in total

Review 1.  Plasminogen activator and hemorrhage in brain tumors.

Authors:  K Oka; H Tsuda; S Sakamoto; Y Go; M Tomonaga
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 2.  Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.

Authors:  J S Rao; P A Steck; P Tofilon; D Boyd; F Ali-Osman; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor.

Authors:  G Salerno; P Verde; M L Nolli; A Corti; H Szöts; T Meo; J Johnson; S Bullock; G Cassani; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

4.  Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.

Authors:  M Osmak; I Vrhovec; J Skrk
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 5.  Invasiveness of primary brain tumors.

Authors:  O D Laerum; R Bjerkvig; S K Steinsvåg; L de Ridder
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.

Authors:  J S Rao; A Rayford; R A Morantz; B W Festoff; R Sawaya
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

7.  Prognostic role of urokinase-type plasminogen activator in human gliomas.

Authors:  D W Hsu; J T Efird; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

8.  Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma.

Authors:  C L Gladson; V Pijuan-Thompson; M A Olman; G Y Gillespie; I Z Yacoub
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

Review 9.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Tumor invasion, proteolysis, and angiogenesis.

Authors:  U P Thorgeirsson; C K Lindsay; D W Cottam; D E Gomez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.